乌帕替尼对中重度特应性皮炎患者手部湿疹的影响:两项随机3期试验结果
两项3期研究(Measure Up 1和2)分析乌帕替尼单药治疗中重度特应性皮炎患者手部湿疹16周的效果。第16周时,乌帕替尼15mg和30mg组HECSI评分较基线改善百分比均大于安慰剂组,且从第1周起即出现改善并维持至第16周。作者认为乌帕替尼可能成为中重度特应性皮炎患者手部湿疹的有效治疗选择。
要点
- 乌帕替尼15mg和30mg单药治疗从第1周起即改善手部湿疹,并维持至第16周。
- 第16周HECSI评分较基线变化:Measure Up 1中15mg组-68%、30mg组-74%、安慰剂组-15%。
- 第16周HECSI评分较基线变化:Measure Up 2中15mg组-68%、30mg组-74%、安慰剂组+21%。
核心结论
- 乌帕替尼15mg和30mg单药治疗在中重度特应性皮炎患者中,相较于安慰剂,从第1周至第16周对手部湿疹提供快速且持续的改善。
- 第16周时,乌帕替尼治疗组HECSI评分的平均改善基于既往可解释性研究具有临床意义。
- 作者认为乌帕替尼可能是中重度特应性皮炎患者手部湿疹的有效治疗选择。
研究设计与样本
- 分析Measure Up 1和Measure Up 2两项研究的数据,患者年龄12-75岁,按1:1:1随机接受乌帕替尼15mg、30mg或安慰剂每日一次。
- 使用手部湿疹严重程度指数(HECSI)评估手部湿疹,HECSI评分较基线的百分比变化为所有访视的预设额外终点。
- HECSI评分改善至少75%(HECSI 75)的患者比例作为事后分析评估。
主要发现
- 接受乌帕替尼15mg或30mg治疗的患者早在第1周即出现HECSI评分较安慰剂更大的改善,并维持至第16周。
- 第16周HECSI评分较基线平均变化:Measure Up 1中乌帕替尼15mg组-68%、30mg组-74%、安慰剂组-15%。
- 第16周HECSI评分较基线平均变化:Measure Up 2中乌帕替尼15mg组-68%、30mg组-74%、安慰剂组+21%(正值表示安慰剂组恶化)。
- 从第1周至第16周的所有时间点,乌帕替尼治疗组达到HECSI 75的患者比例均高于安慰剂组。
关键数值与推荐
- HECSI评分较基线百分比变化为预设额外终点,HECSI 75为事后分析。
- 第16周HECSI评分较基线平均变化:Measure Up 1中乌帕替尼15mg组-68%、30mg组-74%、安慰剂组-15%;Measure Up 2中乌帕替尼15mg组-68%、30mg组-74%、安慰剂组+21%。
临床怎么用
- 作者认为乌帕替尼可能是中重度特应性皮炎患者手部湿疹的有效治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 60% of patients with atopic dermatitis have involvement of the hands adding to the burden of disease. OBJECTIVE: This analysis aims to evaluate the effect of upadacitinib monotherapy on atopic hand eczema in patients with moderate-to-severe AD over 16 weeks in the Measure Up 1 and 2 studies. METHODS: Data from patients (ages 12-75) randomized 1:1:1 to receive upadacitinib 15 mg, 30 mg, or placebo once daily in the Measure Up 1 and 2 studies were analysed for impact on atopic hand eczema assessed using the Hand Eczema Severity Index (HECSI). The percent change from baseline in HECSI score was a prespecified additional endpoint at all visits. The proportion of patients with at least a 75% improvement in HECSI score (HECSI 75) was evaluated post hoc. RESULTS: Patients treated with upadacitinib 15 mg or 30 mg experienced greater improvement in HECSI score compared with placebo as early as Week 1, which was maintained through Week 16. At Week 16, the mean change from baseline in HECSI score for patients receiving upadacitinib 15 mg, 30 mg, and placebo was -68%, -74%, and -15% in Measure Up 1 and -68%, -74% and +21% (positive change indicates worsening for placebo) in Measure Up 2, respectively. A greater proportion of upadacitinib-treated patients achieved HECSI 75 compared with placebo at all timepoints beginning at Week 1 through Week 16. CONCLUSIONS: Upadacitinib 15 mg and 30 mg monotherapy provided rapid and sustained improvement in atopic hand eczema compared with placebo through Week 16 in patients with moderate-to-severe AD. At Week 16, the observed mean improvements in HECSI score in upadacitinib-treated patients were clinically meaningful based on previous interpretability studies. These results suggest that upadacitinib may be an effective treatment option for atopic hand eczema in patients with moderate-to-severe AD.
引用
- Simpson EL, Rahawi K, Hu X, et al. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials. J Eur Acad Dermatol Venereol. 2023. PMID: 37184290. doi:10.1111/jdv.19194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。